HomeAI · summaries
Storia in 3 fonti
Eli Lilly Highlights Positive Foundayo Data At Obesity Conference - Eli Lilly (NYSE:LLY)
Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the…
- ·
statnews.com
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery
